Novo Ends Korro Bio Collaboration Effective 2027
Novo Nordisk has elected to terminate its cardiometabolic research deal with Korro Bio, with the termination set to take effect February 1, 2027.
Updated on Nov. 6, 2026 in Biotech
Novo has elected to terminate its research collaboration and license agreement with Korro Bio, which required 90 days' prior written notice. Korro reported no collaboration revenue for the quarter ending September 30, 2026, compared with $1.1 million a year earlier.
Why it matters
The termination ends a partnership that never advanced to a second target and earned no milestone payments under the agreement. It leaves Korro to continue its own clinical program while Novo will reimburse certain wind-down and committed costs.
The disclosure is an SEC filing reporting that Korro received a $10 million upfront payment and no milestone payments, with collaboration revenue falling to zero from $1.1 million a year earlier. The total wind-down reimbursement amount Novo will pay has not been disclosed in the source.
The players
Novo Nordisk
Novo Nordisk is a Danish pharmaceutical company best known for its diabetes and obesity medicines, including semaglutide.
Korro Bio
Korro Bio is a clinical-stage biotechnology company developing RNA editing therapeutics, including a program for urea cycle disorders.
The details
Korro disclosed the termination in a filing with the U.S. Securities and Exchange Commission after Novo gave written notice of its election to terminate for convenience. The agreement, originally announced September 16, 2024, granted Novo an exclusive worldwide license to certain compounds tied to a cardiometabolic target, and was paused for 12 months under an amendment effective November 11, 2025.
Timeline
September 16, 2024: Korro and Novo announce the original collaboration.
November 11, 2025: The companies amend the agreement, pausing it for 12 months.
2025: Korro completes wind-down of its R&D activities under the agreement.
February 1, 2027: The termination becomes effective.
Big Picture
Early-stage RNA editing collaborations between large drugmakers and smaller biotechs have increasingly been restructured or ended before reaching milestone payments, and Novo's exit from its Korro agreement fits that pattern. The move leaves Korro to advance its own urea cycle disorder program without a partner on the cardiometabolic target.
For most readers the termination has no direct effect, since it concerns a research partnership rather than a commercial product. Its practical relevance is to investors and industry watchers tracking whether Korro's own urea cycle program moves forward on schedule.
The takeaway
Early-stage research partnerships can end well before they produce milestone revenue, so the upfront payment may be the only financial return for the smaller partner. Readers following Korro should watch whether its ANCHOR program meets its first-half 2027 dosing timeline.
What happens next
The termination of the Novo collaboration becomes effective on February 1, 2027, and Korro expects to begin dosing participants in Part two of its ANCHOR program in the first half of 2027.
Further reading
For more on the industry behind this deal, see Biotech.
More information
Read the Korro Bio SEC Form 8-K termination filing for the full terms of the termination.
Source note: This article includes information reported by Pharmexec.
